<DOC>
	<DOCNO>NCT03004924</DOCNO>
	<brief_summary>The purpose study determine investigational treatment effective compare placebo PVP-Iodine treatment adult child bacterial conjunctivitis .</brief_summary>
	<brief_title>Treatment Bacterial Conjunctivitis With SHP640 Compared PVP-Iodine Placebo</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Bacterial</mesh_term>
	<mesh_term>Conjunctivitis , Inclusion</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Povidone-Iodine</mesh_term>
	<criteria>1 . An understanding , ability , willingness fully comply study procedure restriction ( parent ( ) , guardian , legally authorize representative , applicable ) . 2 . Ability voluntarily provide write , sign , date ( personally via parent ( ) , guardian , legallyauthorized representative ( ) inform consent ( assent , applicable ) participate study . 3 . Subjects age Visit 1 ( Note : subject &lt; 3 month age Visit 1 must fullterm , ie &gt; =37 week gestational age birth ) . 4 . Have positive AdenoPlus® test Visit 1 least 1 eye . 5 . Have clinical diagnosis suspect adenoviral conjunctivitis least 1 eye ( eye AdenoPlus positive eye ) confirm presence follow minimal clinical sign symptom eye : Report presence sign and/or symptoms adenoviral conjunctivitis ≤ 3 day prior Visit 1 Bulbar conjunctival injection : grade &gt; =1 04 scale Bulbar Conjunctival Injection Scale Watery conjunctival discharge : grade &gt; =1 ( mild ) 03 Watery Conjunctival Discharge Scale 6 . Be willing discontinue contact lens wear duration study . 7 . Have Best Corrected Visual Acuity ( BCVA ) 0.60 logMAR good eye measure use Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart . BCVA assess age appropriate method accordance AAP Policy Statement Visual System Assessment Infants , Children , Young Adults Pediatricians ( Donahue Baker , 2016 ; American Academy Pediatrics , 2016 ) . The policy statement recommend formal vision screen begin 3 year age . VA measurement child age 3 do discretion investigator . If do , child able fixate follow move object , except subject &lt; 2 month age yet develop ability . Subjects &lt; 2 month enrol discretion Investigator . 8 . Male , nonpregnant , nonlactating female agree comply applicable contraceptive requirement protocol female nonchildbearing potential . Subjects exclude study follow exclusion criterion meet . 1 . Current recurrent disease could affect action , absorption , disposition investigational product , clinical laboratory assessment , per investigator 's discretion . 2 . Current relevant history physical psychiatric illness , medical disorder may make subject unlikely fully complete study , condition present undue risk investigational product procedure . 3 . Have know suspected intolerance hypersensitivity investigational product , closely related compound , state ingredient . 4 . Prior enrollment FST100 SHP640 clinical study . 5 . Subjects employee , immediate family member employee ( directly relate study conduct ) , investigational site . 6 . Have history ocular surgical intervention within ≤ 6 month prior Visit 1 plan period study . 7 . Have preplanned overnight hospitalization period study . 8 . Have presence intraocular , corneal , conjunctival ocular inflammation ( eg , uveitis , iritis , ulcerative keratitis , chronic blepharoconjunctivitis ) , adenoviral conjunctivitis . 9 . Have presence corneal subepithelial infiltrates Visit 1 10 . Have active history ocular herpes . 11 . Have enrollment within ≤30 day Visit 1 , clinical presentation consistent diagnosis ocular allergy , toxic conjunctivitis , nonadenoviral ocular infection ( eg , bacterial , fungal , acanthamoebal , parasitic ) . 12 . Neonates infant ( ie . subject less 12 month age ) suspect confirm ( base result test conduct prior screen ) conjunctivitis gonococcal , chlamydial , herpetic chemical origin . 13 . Neonates infant ( ie . subject less 12 month age ) whose birth mother sexually transmit disease within 1 month delivery history genital herpes . 14 . Presence nasolacrimal duct obstruction Visit 1 ( Day 1 ) . 15 . Presence significant ophthalmic condition ( eg , Retinopathy Prematurity , congenital cataract , congenital glaucoma ) congenital disorder ophthalmic involvement could affect study variable . 16 . Be know intraocular pressure ( IOP ) steroid responder , know history glaucoma , glaucoma suspect , know history elevate IOP &gt; 21 mmHg . 17 . Have know clinically significant optic nerve defect . 18 . Have history recurrent corneal erosion syndrome , either idiopathic secondary previous corneal trauma dry eye syndrome ; presence corneal epithelial defect significant corneal opacity Visit 1 . 19 . Presence significant , active condition posterior segment require invasive treatment ( eg , intravitreal treatment VEGF inhibitor corticosteroid ) may progress study participation period . 20 . Have use topical ocular systemic antiviral antibiotic within &lt; = 7 day enrollment . 21 . Have use topical ocular NSAIDs within &lt; =1 day enrollment . 22 . Have use topical ophthalmic steroid last &lt; =14 day . 23 . Have use systemic corticosteroid agent within &lt; =14 day Day 1 . Stable ( initiated ≥30 day prior enrollment ) use inhale nasal corticosteroid allow , give anticipated change dose duration study . Topical dermal steroid allow except periocular area . 24 . Have use noncorticosteroid immunosuppressive agent within &lt; =14 day Day 1 . 25 . Have use topical ophthalmic product , include tear substitute , overthecounter preparation lid scrub , within 2 hour Visit 1 unable discontinue topical ophthalmic product duration study . Use hot cold compress also permit study . 26 . Have significant ocular disease ( eg , Sjogren 's syndrome ) uncontrolled systemic disease debilitate disease ( eg , cardiovascular disease , hypertension , sexually transmitted diseases/infections , diabetes cystic fibrosis ) , may affect study parameter , per Investigator 's discretion . 27 . Any known history immunodeficiency disorder know active condition predispose immunodeficiency , human immunodeficiency virus , hepatitis B C , evidence active hepatitis A ( antihepatitis A virus immunoglobulin M ) , organ bone marrow transplantation . 28 . Within 30 day prior first dose investigational product : Have use investigational product device , Have enrol clinical study ( include vaccine study ) , investigator 's opinion , may impact Shiresponsored study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>